Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis.

In addition, by reducing the number of dose adjustments through an individualized initial dose may improve the feasibility of using TAC in clinical practice because turnaround of TAC trough level measurement takes more than a day in many institutions, even though difference in efficacy did not reach statistical significance which may be due to a small sample size.

also in 111,027 other papers